Stefaan Van Gool MD. PhD.
Medizinischer Leiter der Translationalen Onkologie am IOZK
Tumorimmunologe mit Schwerpunkt Hirntumore
Stefaan Van Gool MD. PhD., ist Facharzt für pädiatrische Hämato-Onkologie mit dem Schwerpunkt Hirntumore. Von 2001 bis 2004 war er Leitender klinischer Prüfarzt am Förderfonds für wissenschaftliche Forschung Flandern. Zwischen 2006 und 2016 hatte er eine Ordentliche Professur an der medizinischen Fakultät der Katholischen Universität Leuven inne. Dort leitete er von 2012 bis 2015 das Labor für Pädiatrische Immunologie. Er ist Autor von annähernd 200 wissenschaftlichen Artikeln in internationalen Journalen.
In Anerkennung seiner wissenschaftlichen Leistungen erhielt er eine Vielzahl von Ehrungen:
1995 Schweisguth Preis der International Society of Paediatric Oncology
1996 Nycomed Preis der International Society of Paediatric Oncology
1998 Preis der Rik en Nel Wouters-Stiftung für Krebsforschung (mit Ludwig Van den Hove)
Von 2005 bis 2009 war er der Koordinator der europäischen Expertengruppe für High Grade Glioma
Seit 2008 ist er Mitglied des Obersten Gesundheitsgerichtshofs in Belgien
Von 2014 bis 2017 fungierte er als Ko-Vorsitzender der Arbeitsgruppe Hirntumore der European Society for Paediatric Oncology.
Am IOZK steht er dem Ärzteteam vor und ist verantwortlich für die Planung und Durchführung der IOZK-Immuntherapie. In der Arzneimittelherstellung fungiert er als Sachkundige Person (GMP) und verantwortliche ärztliche Person.
Sammlung: Wissenschaftliche Beiträge und internationale Publikationen von Stefaan Van Gool MD. PhD
„Da jeder Tumor anders ist, erzielt man die besten Ergebnisse, wenn man mit patienteneigenen dendritischen Zellen gegen den einzigartigen Satz von Tumorzellen vorgeht“
Stefaan Van Gool MD. PhD.
Weitere Informationen zu diesem Thema:
This post is also available in: Russisch
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
/in Dendritic Cells, Hyperthermia, International Publications, Newcastle Disease Virus /von 2020-07-23 / Biomedicines 2020 Jul;8(8)PMID: 32717895 Journal: Biomedicines (volume: 8, issue: 8, Biomedicines 2020 Jul;8(8)) Published: 2020-07-23 Authors: Schirrmacher V, Sprenger T, Stuecker W, Van Gool SW ABSTRACT At times of personalized and individualized medicine the concept of randomized- controlled clinical trials (RCTs) is being questioned. This review article explains principles of evidence-based medicine in oncology and shows an […]
Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
/in Dendritic Cells, Hyperthermia, International Publications, Newcastle Disease Virus /von 2020-06-30 / Expert Rev Anticancer Ther 2020 Jun;:1-8PMID: 32600076 Journal: Expert review of anticancer therapy (volume: , issue: , Expert Rev Anticancer Ther 2020 Jun;:1-8) Published: 2020-06-30 Authors: Sprenger T, Schirrmacher V, Stücker W, van Gool SW ABSTRACT INTRODUCTION: Prospective double-blind placebo-controlled randomized clinical trials (RCTs) are considered standard for the proof of the efficacy of oncologic therapies. Molecular methods have provided […]
IOZK Analyse belegt gute Verträglichkeit der IOZK Immuntherapie beim Diffusen intrinsischen pontinen Gliom (DIPG)
/in IOZK Veröffentlichungen /von IOZKDas Team des IOZK veröffentlicht mit einer internationalen Gruppe von Wissenschaftlern aus Deutschland, der Schweiz und den USA eine retrospektive Analyse zur Anwendung der IOZK-Immuntherapie beim Diffusen intrinsischen pontinen Gliom (DIPG). Es belegt die gute Verträglichkeit und möglichen klinischen Nutzen der Kombination aus Impfung mit Dendritischen Zellen, onkolytischer Virotherapie mit dem Newcastle Disease Virus und […]
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
/in Dendritic Cells, Exosome, Hyperthermia, International Publications, Newcastle Disease Virus /von 2020-03-01 / J Immunother Cancer 2020 Mar;8(1)PMID: 32209603 Journal: Journal for immunotherapy of cancer (volume: 8, issue: 1, J Immunother Cancer 2020 Mar;8(1)) Published: 2020-03-01 Authors: Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, Draganov D, Edelson RL, Formenti SC, Fucikova J, Gabriele L, Gaipl US, Gameiro SR, Garg […]
Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease Virus /von 2019-08-30 / Biomedicines 2019 Aug;7(3)PMID: 31480379 Journal: Biomedicines (volume: 7, issue: 3, Biomedicines 2019 Aug;7(3)) Published: 2019-08-30 Authors: Schirrmacher V, van Gool S, Stuecker W ABSTRACT Resistance to therapy is a major obstacle to cancer treatment. It may exist from the beginning, or it may develop during therapy. The review focusses on oncolytic Newcastle disease virus (NDV) as a […]
Symposium & Fortbildung am IOZK: Immuntherapie in der Neuroonkologie, Fr. 06.09.2019
/in IOZK bei Fachtagungen, IOZK Meldungen /von IOZKDie Immuntherapie hat sich in den letzten Jahren neben Chirurgie, Strahlen- und Chemotherapie als die vierte Säule der Krebstherapie etabliert. Die Anwendung der Immuntherapie in der Neuroonkologie ist mit besonderen Herausforderungen aber auch mit großen Hoffnungen verbunden. Das IOZK wird anlässlich der Eröffnung seines neuen GMP-Labors ein wissenschaftliches Symposium mit internationalen Referenten zum Thema „Immuntherapie […]
Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy
/in Dendritic Cells, Glioblastoma, International Publications /von 2019-04-01 / Anticancer Res. 2019 Apr;39(4):2043-2051PMID: 30952748 Journal: Anticancer research (volume: 39, issue: 4, Anticancer Res. 2019 Apr;39(4):2043-2051) Published: 2019-04-01 Authors: Antonopoulos M, VAN Gool SW, Dionysiou D, Graf N, Stamatakos G ABSTRACT BACKGROUND/AIM: The need for more effective treatment modalities that can improve the clinical outcome of patients with glioblastoma multiforme remains imperative. Dendritic cell vaccination is a fast-developing […]
IOZK-Artikel über Heilversuche bei Glioblastom im Fachorgan: „Austin Oncology Case Report“
/in IOZK Veröffentlichungen /von rootDie IOZK-Arbeitsgruppe publizierte einen wissenschaftlichen Artikel im Fachorgan „Austin Oncology Case Report“. In dieser Arbeit wurden retrospektiv Patienten mit Glioblastom im Rahmen individueller Heilversuche untersucht – unter der tumorspezifischen Immunmodulation mittels modulierter Elektro-Hyperthermie in Kombination mit onkolytischer Virotherapie – zusätzlich zur Chemotherapie mit Temodal. Die adjuvante Therapie gibt Hinweise auf einen besseren Therapieeffekt, wenn neben […]
IOZK Vortrag: Modulierte Elektro-Hyperthermie bei Kindern mit DIPG, Konferenz der ESHO, Charité Berlin
/in IOZK bei Fachtagungen, IOZK Meldungen /von IOZKDas IOZK nahm an der jährlichen Konferenz der ESHO (European Society for Hyperthermic Oncology) teil, die an der Berliner Universitätsklinik – Charité stattfand. Thema des IOZK-Vortrags war die modulierte Elektro-Hyperthermie als Teil der Behandlung von Kindern mit DIPG, einem aggressiven Hirntumor (Hyperthermia as part of multimodal immunotherapy for children with DIPG, S. van Gool, J. Makalowski, V. Schirrmacher, […]
IOZK Vortrag über die Effekte der multimodalen Immuntherapie bei einem Ponsgliom mit Hilfe der Analysemethode Flüssigbiopsie.
/in Externe Meldungen, IOZK bei Fachtagungen /von rootAn der George Washington Universität in Washington D.C. fanden am 11. April die GW Research-Days statt. Dort berichtete die Arbeitsgruppe von Roger J. Packer und Javad Nazarian (Children’s National Health System, Washington / George Washington University / IOZK) über die Effekte der multimodalen Immuntherapie bei einem Ponsgliom mit Hilfe der Analysemethode Flüssigbiopsie. Ponsgliome sind inoperable Tumore, die […]
IOZK Vortrag von Stefaan Van Gool: IOZK Immuntherapie bei DIPG Ponsgliom, Konferenz der Society for Neuro-Oncology, San Francisco
/in IOZK bei Fachtagungen, IOZK Meldungen /von IOZKStefaan Van Gool stellte auf der der Konferenz der Society for Neuro-Oncology in San Francisco, kurz SNO genannt, die multimodale Immuntherapie bei DIPG (Ponsgliom) vor, ein Hirntumor, der vor allem bei Kindern auftritt. SNO ist eine multidisziplinäre Organisation, die den Fokus auf Fortschritte in der Neuro-Onkologie durch Forschung und Lehre setzt. Kombination war in diesem Jahr das Schlüsselwort […]
IOZK Artikel im Austin Oncology Case Reports über Krebsimpfstoffe
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKIm amerikanischen Fachorgan Austin Oncology Case Reports publiziert das IOZK in der Sonderausgabe zu Krebsimpfstoffen einen Beitrag, der die Strategie der spezifischen Immuntherapie beschreibt und erläutert. A New Strategy of Cancer Immunotherapy Combining Hyperthermia/Oncolytic Virus Pretreatment with Specific Autologous Anti-Tumor Vaccination
Artikel über Stefaan Van Gool als Kinderneuroonkologe in der Washington Post
/in IOZK In der Presse /von IOZKDie Behandlung von kindlichen Hirntumoren ist ein Schwerpunkt im Behandlungsspektrum des IOZK, da Stefaan Van Gool als Kinderneuroonkologe darauf spezialisiert ist. Diese Tätigkeit findet bei Betroffenen international Beachtung, wie ein aktueller Bericht in der Washington Post belegt. A young boy, a devastating brain tumor and parents who ‘will do anything’
Immunotherapy in atypical teratoid-rhabdoid tumors: Data from a survey of the HGG-Immuno Group
/in Brain Tumors in Children, Dendritic Cells, International Publications /von 2016-07-12 / Cytotherapy 2016 09;18(9):1178-86PMID: 27421737 Journal: Cytotherapy (volume: 18, issue: 9, Cytotherapy 2016 09;18(9):1178-86) Published: 2016-07-12 Authors: van Gool SW, Holm S, Rachor J, Adamson L, Technau A, Maass E, Frühwald MC, Schlegel PG, Eyrich M ABSTRACT BACKGROUND AIMS: Atypical rhabdoid/teratoid tumors (AT/RT) are the most common brain tumors in infants and associated with a dismal prognosis. Although […]
Veröffentlichung von Stefaan Van Gool MD. PhD.: Electroporation of Dendritic Cells with WT1, Survivin, and TriMix
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKStefan Van Gool ist Mitautor einer wissenschaftlichen Veröffentlichung über eine spezielle Form der Aufbereitung Dendritischer Zellen (in Englisch). Electroporation of Dendritic Cells with WT1, Survivin, and TriMix
Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma
/in Dendritic Cells, Glioblastoma, International Publications /von 2016-03-02 / Sci Transl Med 2016 Mar;8(328):328ra27PMID: 26936504 Journal: Science translational medicine (volume: 8, issue: 328, Sci Transl Med 2016 Mar;8(328):328ra27) Published: 2016-03-02 Authors: Garg AD, Vandenberk L, Koks C, Verschuere T, Boon L, Van Gool SW, Agostinis P ABSTRACT The promise of dendritic cell (DC)-based immunotherapy has been established by two decades of translational research. Of the four malignancies most […]
IOZK Beitrag in der Fachzeitschrift für Orthomolekulare Medizin, Sonderheft: Onkologie
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKIm Sonderheft Onkologie von „OM & Ernährung: Fachzeitschrift für Orthomolekulare Medizin“ veröffentlichen Prof. Van Gool und Dr. Stücker einen Beitrag zur Kombination von „Checkpoint-Inhibitoren“ mit der spezifischen Immuntherapie, wie sie im IOZK angewandt wird. Mit zusätzlichen Therapieoptionen die Wirkung von Checkpoint-Inhibitoren – die neuen Hoffnungsträger der Onkologie – steigern!
Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines
/in Dendritic Cells, Hyperthermia, International Publications /von 2016-01-14 / Front Immunol 2015;6:663PMID: 26834740 Journal: Frontiers in immunology (volume: 6, issue: , Front Immunol 2015;6:663) Published: 2016-01-14 Authors: Vandenberk L, Belmans J, Van Woensel M, Riva M, Van Gool SW ABSTRACT Cancer immunotherapy is currently the hottest topic in the oncology field, owing predominantly to the discovery of immune checkpoint blockers. These promising antibodies and their attractive […]
Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma
/in Dendritic Cells, Glioblastoma, International Publications /von 2015-09-11 / Oncoimmunology 2016 Feb;5(2):e1083669PMID: 27057467 Journal: Oncoimmunology (volume: 5, issue: 2, Oncoimmunology 2016 Feb;5(2):e1083669) Published: 2015-09-11 Authors: Vandenberk L, Garg AD, Verschuere T, Koks C, Belmans J, Beullens M, Agostinis P, De Vleeschouwer S, Van Gool SW ABSTRACT Dendritic cell (DC)-based immunotherapy has yielded promising results against high-grade glioma (HGG). However, the efficacy of DC vaccines is abated […]
Stefaan Van Gool wechselt von der Universität Leuven zum IOZK
/in IOZK Meldungen /von IOZKDer international anerkannte Immunologe forscht und arbeitet seit 20 Jahren an der Universität Leuven in Belgien. Seine besonderen Schwerpunkte sind Pädiatrische Neuro-Onkologie und histiozytäre Erkrankungen Tumor-Immunologie: Präklinische Forschung und klinische Studien im Bereich der Hirntumoren Langzeit- und Spätfolgen der Chemotherapie Ein wesentlicher Grund für den Wechsel zum IOZK war die im Mai erfolgte Herstellungserlaubnis für den ersten […]
Tumour Relapse Prediction Using Multiparametric MR Data Recorded during Follow-Up of GBM Patients
/in Glioblastoma, International Publications /von 2015-08-27 / Biomed Res Int 2015;2015:842923PMID: 26413548 Journal: BioMed research international (volume: 2015, issue: , Biomed Res Int 2015;2015:842923) Published: 2015-08-27 Authors: Ion-Margineanu A, Van Cauter S, Sima DM, Maes F, Van Gool SW, Sunaert S, Himmelreich U, Van Huffel S ABSTRACT PURPOSE: We have focused on finding a classifier that best discriminates between tumour progression and regression based on […]
Brain Tumor Immunotherapy: What have We Learned so Far?
/in Dendritic Cells, Glioblastoma, International Publications /von 2015-06-17 / Front Oncol 2015;5:98PMID: 26137448 Journal: Frontiers in oncology (volume: 5, issue: , Front Oncol 2015;5:98) Published: 2015-06-17 Authors: Van Gool SW ABSTRACT High grade glioma is a rare brain cancer, incurable in spite of modern neurosurgery, radiotherapy, and chemotherapy. Novel approaches are in research, and immunotherapy emerges as a promising strategy. Clinical experiences with active specific immunotherapy […]
Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model
/in Dendritic Cells, Glioblastoma, International Publications /von 2015-06-13 / J. Neurooncol. 2015 Sep;124(2):325-32PMID: 26070556 Journal: Journal of neuro-oncology (volume: 124, issue: 2, J. Neurooncol. 2015 Sep;124(2):325-32) Published: 2015-06-13 Authors: Müller K, Henke G, Pietschmann S, van Gool S, De Vleeschouwer S, von Bueren AO, Compter I, Friedrich C, Matuschek C, Klautke G, Kortmann RD, Hundsberger T, Baumert BG ABSTRACT We aimed to compare two different salvage treatment strategies […]
Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2015-01-15 / J Cancer 2015;6(3):203-17PMID: 25663937 Journal: Journal of Cancer (volume: 6, issue: 3, J Cancer 2015;6(3):203-17) Published: 2015-01-15 Authors: Koks CA, De Vleeschouwer S, Graf N, Van Gool SW ABSTRACT Oncolytic viruses have been seriously considered for glioma therapy over the last 20 years. The oncolytic activity of several oncolytic strains has been demonstrated against human glioma cell […]
Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2014-09-19 / Int. J. Cancer 2015 Mar;136(5):E313-25PMID: 25208916 Journal: International journal of cancer (volume: 136, issue: 5, Int. J. Cancer 2015 Mar;136(5):E313-25) Published: 2014-09-19 Authors: Koks CA, Garg AD, Ehrhardt M, Riva M, Vandenberk L, Boon L, De Vleeschouwer S, Agostinis P, Graf N, Van Gool SW ABSTRACT The oncolytic features of several naturally oncolytic viruses have been shown on Glioblastoma […]
Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells
/in Dendritic Cells, International Publications /von 2014-05-13 / Cytotherapy 2014 Jul;16(7):946-64PMID: 24831836 Journal: Cytotherapy (volume: 16, issue: 7, Cytotherapy 2014 Jul;16(7):946-64) Published: 2014-05-13 Authors: Eyrich M, Schreiber SC, Rachor J, Krauss J, Pauwels F, Hain J, Wölfl M, Lutz MB, de Vleeschouwer S, Schlegel PG, Van Gool SW ABSTRACT BACKGROUND AND AIMS: One of the major challenges of dendritic cell (DC) vaccination is the establishment […]
Wilms‘ tumor gene 1 immunotherapy in pelvic gynecological malignancies
/in Dendritic Cells, International Publications, Ovarian Cancer, Uterine Cancer /von 2014-05-02 / Expert Rev Clin Immunol 2014 Jun;10(6):705-11PMID: 24784346 Journal: Expert review of clinical immunology (volume: 10, issue: 6, Expert Rev Clin Immunol 2014 Jun;10(6):705-11) Published: 2014-05-02 Authors: Coosemans A, Vergote I, Van Gool SW ABSTRACT Pelvic gynecological malignancies account for 6% of all cancers. In the relapsed state, classical treatments are limited. There is an urgent need for new and personalized […]
Dendritic cell immunotherapy in uterine cancer
/in Dendritic Cells, International Publications, Uterine Cancer /von 2014-01-01 / Hum Vaccin Immunother 2014;10(7):1822-7PMID: 25424788 Journal: Human vaccines & immunotherapeutics (volume: 10, issue: 7, Hum Vaccin Immunother 2014;10(7):1822-7) Published: 2014-01-01 Authors: Coosemans A, Tuyaerts S, Vanderstraeten A, Vergote I, Amant F, Van Gool SW ABSTRACT Uterine cancer is the most common pelvic gynecological malignancy. Uterine sarcomas and relapsed uterine carcinomas have limited treatment options. The search for new […]
Wilms‘ Tumor Gene 1 (WT1)–loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial
/in Dendritic Cells, International Publications, Uterine Cancer /von 2013-12-01 / Anticancer Res. 2013 Dec;33(12):5495-500PMID: 24324087 Journal: Anticancer research (volume: 33, issue: 12, Anticancer Res. 2013 Dec;33(12):5495-500) Published: 2013-12-01 Authors: Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman ZN, Vergote I, Amant F, VAN Gool SW ABSTRACT AIM: Treatment options are limited in uterine cancer, leading to a poor prognosis. Overexpression of Wilms‘ tumor gene 1 […]
Myeloid-derived suppressor cells in glioma
/in Glioblastoma, International Publications /von 2013-11-12 / Expert Rev Neurother 2013 Dec;13(12):1395-406PMID: 24215283 Journal: Expert review of neurotherapeutics (volume: 13, issue: 12, Expert Rev Neurother 2013 Dec;13(12):1395-406) Published: 2013-11-12 Authors: Mirghorbani M, Van Gool S, Rezaei N ABSTRACT Glioblastoma is the most prevalent form of gliomas with high aggressive nature and high recurrence. Despite aggressive therapy, including surgery, chemotherapy and radiotherapy, median patient survival is only […]
Dendritic cell-based immunotherapy in ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2013-11-06 / Oncoimmunology 2013 Dec;2(12):e27059PMID: 24501688 Journal: Oncoimmunology (volume: 2, issue: 12, Oncoimmunology 2013 Dec;2(12):e27059) Published: 2013-11-06 Authors: Coosemans A, Vergote I, Van Gool SW ABSTRACT Worldwide, 80% of patients with ovarian cancer die of the disease. New treatments for this aggressive disease are therefore being intensively searched. Although dendritic cell-based vaccines against gynecological malignancies are in their infancy, […]
Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials
/in Glioblastoma, International Publications /von 2013-10-01 / Immunotherapy 2013 Oct;5(10):1043-6PMID: 24138559 Journal: Immunotherapy (volume: 5, issue: 10, Immunotherapy 2013 Oct;5(10):1043-6) Published: 2013-10-01 Authors: van Gool S ABSTRACT Evaluation of: Lasky JL 3rd, Panosyan EH, Plant A et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res. 33, 2047-2056 (2013). Immunotherapy for children and adults […]
Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2013-09-01 / Anticancer Res. 2013 Sep;33(9):3855-9PMID: 24023319 Journal: Anticancer research (volume: 33, issue: 9, Anticancer Res. 2013 Sep;33(9):3855-9) Published: 2013-09-01 Authors: Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman Z, Vergote I, Amant F, Van Gool SW ABSTRACT BACKGROUND: Dendritic cell (DC)-based immunotherapy is an emerging new treatment option in ovarian cancer, an important cause of cancer-related […]
Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?
/in Glioblastoma, International Publications /von 2013-08-14 / Cancers (Basel) 2013 Aug;5(3):1020-48PMID: 24202332 Journal: Cancers (volume: 5, issue: 3, Cancers (Basel) 2013 Aug;5(3):1020-48) Published: 2013-08-14 Authors: van Woensel M, Wauthoz N, Rosière R, Amighi K, Mathieu V, Lefranc F, van Gool SW, de Vleeschouwer S ABSTRACT Despite recent advances in tumor imaging and chemoradiotherapy, the median overall survival of patients diagnosed with glioblastoma multiforme does not […]
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
/in Dendritic Cells, Glioblastoma, International Publications /von 2012-04-22 / Cancer Immunol. Immunother. 2012 Nov;61(11):2033-44PMID: 22527250 Journal: Cancer immunology, immunotherapy : CII (volume: 61, issue: 11, Cancer Immunol. Immunother. 2012 Nov;61(11):2033-44) Published: 2012-04-22 Authors: Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, Sciot R, Wilms G, Demaerel P, Goffin J, Van Calenbergh F, Menten J, Clement P, Debiec-Rychter M, De Vleeschouwer S ABSTRACT PURPOSE: Dendritic cell […]
Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma
/in Dendritic Cells, Endometrial Cancer, International Publications /von 2010-09-01 / Anticancer Res. 2010 Sep;30(9):3709-14PMID: 20944158 Journal: Anticancer research (volume: 30, issue: 9, Anticancer Res. 2010 Sep;30(9):3709-14) Published: 2010-09-01 Authors: Coosemans A, Wölfl M, Berneman ZN, Van Tendeloo V, Vergote I, Amant F, Van Gool SW ABSTRACT BACKGROUND: Wilms‘ tumour gene 1 (WT1), a highly ranked immunotherapeutic target, is expressed in uterine cancer and therefore WT1 immunotherapy may present […]
Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours
/in Brain Tumors in Children, Dendritic Cells, Glioblastoma, International Publications /von 2010-04-01 / Pediatr Blood Cancer 2010 Apr;54(4):519-25PMID: 19852061 Journal: Pediatric blood & cancer (volume: 54, issue: 4, Pediatr Blood Cancer 2010 Apr;54(4):519-25) Published: 2010-04-01 Authors: Ardon H, De Vleeschouwer S, Van Calenbergh F, Claes L, Kramm CM, Rutkowski S, Wolff JE, Van Gool SW ABSTRACT BACKGROUND: A large experience with dendritic cell (DC)-based vaccination for malignant brain tumours has been gained […]
Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination
/in Glioblastoma, International Publications /von 2009-10-27 / J. Immunol. Methods 2010 Jan;352(1-2):169-73PMID: 19874827 Journal: Journal of immunological methods (volume: 352, issue: 1-2, J. Immunol. Methods 2010 Jan;352(1-2):169-73) Published: 2009-10-27 Authors: Ardon H, Verbinnen B, Maes W, Beez T, Van Gool S, De Vleeschouwer S ABSTRACT We have successfully treated over two hundred high-grade glioma (HGG) patients with immunotherapy consisting of vaccination with autologous dendritic cells (DCs) […]
Dendritic cell therapy of high-grade gliomas
/in Glioblastoma, International Publications /von 2009-10-01 / Brain Pathol. 2009 Oct;19(4):694-712PMID: 19744041 Journal: Brain pathology (Zurich, Switzerland) (volume: 19, issue: 4, Brain Pathol. 2009 Oct;19(4):694-712) Published: 2009-10-01 Authors: Van Gool S, Maes W, Ardon H, Verschuere T, Van Cauter S, De Vleeschouwer S ABSTRACT The prognosis of patients with malignant glioma is poor in spite of multimodal treatment approaches consisting of neurosurgery, radiochemotherapy and maintenance […]
Vaccine therapy in patients with renal cell carcinoma
/in Hypernephroma, International Publications /von 2009-01-30 / Eur. Urol. 2009 Jun;55(6):1333-42PMID: 19201522 Journal: European urology (volume: 55, issue: 6, Eur. Urol. 2009 Jun;55(6):1333-42) Published: 2009-01-30 Authors: Van Poppel H, Joniau S, Van Gool SW ABSTRACT CONTEXT: Renal cell carcinoma (RCC) is one of the most immunoresponsive cancers in humans. Although immunotherapy is currently much less used than in the past, it remains an important option […]
Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme
/in Dendritic Cells, Glioblastoma, International Publications /von 2008-05-15 / Clin. Cancer Res. 2008 May;14(10):3098-104PMID: 18483377 Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (volume: 14, issue: 10, Clin. Cancer Res. 2008 May;14(10):3098-104) Published: 2008-05-15 Authors: De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, Soerensen N, Wolff […]
Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells
/in Glioblastoma, International Publications /von 2007-03-15 / J. Neurooncol. 2007 Sep;84(2):131-40PMID: 17361330 Journal: Journal of neuro-oncology (volume: 84, issue: 2, J. Neurooncol. 2007 Sep;84(2):131-40) Published: 2007-03-15 Authors: De Vleeschouwer S, Spencer Lopes I, Ceuppens JL, Van Gool SW ABSTRACT Injection of dendritic cells (DC) pulsed with tumor antigens is a novel treatment strategy against malignancies, and aims to elicit anti-tumoral cell-mediated immune responses. We studied […]
Dendritic cell vaccination in patients with malignant gliomas: current status and future directions
/in Glioblastoma, International Publications /von 2006-11-01 / Neurosurgery 2006 Nov;59(5):988-99; discussioin 999-1000PMID: 17143233 Journal: Neurosurgery (volume: 59, issue: 5, Neurosurgery 2006 Nov;59(5):988-99; discussioin 999-1000) Published: 2006-11-01 Authors: de Vleeschouwer S, Rapp M, Sorg RV, Steiger HJ, Stummer W, van Gool S, Sabel M ABSTRACT OBJECTIVE: Despite recent advances in neurosurgical resection techniques, radiation therapy, and chemotherapy, malignant gliomas continue to have a dismal prognosis because relapses […]
Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study
/in Dendritic Cells, Glioblastoma, International Publications /von 2004-11-01 / Br. J. Cancer 2004 Nov;91(9):1656-62PMID: 15477864 Journal: British journal of cancer (volume: 91, issue: 9, Br. J. Cancer 2004 Nov;91(9):1656-62) Published: 2004-11-01 Authors: Rutkowski S, De Vleeschouwer S, Kaempgen E, Wolff JE, Kühl J, Demaerel P, Warmuth-Metz M, Flamen P, Van Calenbergh F, Plets C, Sörensen N, Opitz A, Van Gool SW ABSTRACT Patients with relapsed malignant glioma have […]
Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report
/in Brain Tumors in Children, Dendritic Cells, Glioblastoma, International Publications /von 2004-05-01 / J. Neurosurg. 2004 May;100(5 Suppl Pediatrics):492-7PMID: 15287461 Journal: Journal of neurosurgery (volume: 100, issue: 5 Suppl Pediatrics, J. Neurosurg. 2004 May;100(5 Suppl Pediatrics):492-7) Published: 2004-05-01 Authors: De Vleeschouwer S, Van Calenbergh F, Demaerel P, Flamen P, Rutkowski S, Kaempgen E, Wolff JE, Plets C, Sciot R, Van Gool SW ABSTRACT Treatment of malignant glioma is difficult and discouraging. Even after […]